Clinical Task Force Update

Similar documents
Results of Crosswalk Study

CNADC NIA ADC Clinical Task Force UDS Neuropsychology Work Group April 2011

The National Institute on Aging (NIA) of the National

UDS version 3 Summary of major changes to UDS form packets

ADC Directors Meeting

Papers recently published using NACC data. Lilah Besser, PhD, MSPH

Alzheimer s Disease Genetics Consortium (ADGC) University of Pennsylvania School of Medicine

NACC News. ADC Directors Meeting Atlanta, GA 20 Oct 2018

Exploration of a weighed cognitive composite score for measuring decline in amnestic MCI

A Web-Based Normative Calculator for the Uniform Data Set (UDS) Neuropsychological Test Battery

Neuropsychologic evaluation has played a central role in

FINAL AGENDA Administrators Meeting

Alzheimer s Disease Genetics Consortium ADGC. Alzheimer s Disease Sequencing Project ADSP

Equating UDS Neuropsychological Tests: 3.0>2.0, 3.0=2.0, 3.0<2.0? Dan Mungas, Ph.D. University of California, Davis

Recent publications using the NACC Database. Lilah Besser

Migrating from UDS 2.0 to UDS 3.0: Modern psychometric methods. Paul K. Crane, MD MPH Department of Medicine University of Washington

Neurology for the Non Neurologist

Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods. Christos Davatzikos, Ph.D.

Form D1: Clinician Diagnosis

AD Prevention Trials: An Industry Perspective

Version 3.0, March 2015

3/7/2017. Alzheimer s and Dementia Research: An Advanced Discussion. Alzheimer s and Dementia Research: An Advanced Discussion

Mild Cognitive Impairment (MCI)

Re: Request for Information: Updating the Alzheimer s Disease-Related Dementias Research Priorities

Form A3: Subject Family History

NIH Alzheimer s Disease Centers Panel Recommendations

Predictors of Reversion from Mild Cognitive Impairment to Normal Cognition

Assessment for the Model Predicting of the Cognitive and Language Ability in the Mild Dementia by the Method of Data-Mining Technique

The Relationship Between Cognitive Functioning and the JNC-8 Guidelines for Hypertension in Older Adults

Secure Medicine Return in King County, WA. Margaret Shield, Local Hazardous Waste Management Program in King County October 16, 2013

Neuropsychological Evaluation of

Molecular Imaging Heterogeneity of Clinically Defined AD

NEXT-Link DEMENTIA. A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES.

Becoming Donor-Centered....what donors want and how to lead your team in adopting Donor-Centered Fundraising

ADGC and NIAGADS Update October 2014 ADC Director s Meeting. Li-San Wang University of Pennsylvania

Update on the DLB Module. ADC Directors Meeting Baltimore, MD October 14-15, 2016

Associations between Dementia Diagnosis and Hyperpolypharmacy: Jointly accounting for Dropout and Death

Baseline Characteristics of Patients Attending the Memory Clinic Serving the South Shore of Boston

Traumatic brain injury (TBI) is a major public health. Original Articles. Clinical Phenotype of Dementia after Traumatic Brain Injury

NIH Public Access Author Manuscript J Int Neuropsychol Soc. Author manuscript; available in PMC 2010 August 12.

CREATION OF A TORONTO CENTRE FOR DEMENTIA RESEARCH

September 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by

Aging Centers and Networks accessing the colleagues and mentors you need

Update on the DLB Module. ADC Directors Meeting Baltimore, MD October 14-15, 2016

The Alzheimer s Disease Centers Program: updates

Port of Portland Hillsboro Airport Master Plan Update Planning Advisory Committee Charter

NATIONAL QUALITY FORUM

DATA CORE MEETING. Observational studies in dementia and the MELODEM initiative. V. Shane Pankratz, Ph.D.

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018

Selection and Combination of Markers for Prediction

Clinical and Cognitive Features of DLB. James E. Galvin, MD, MPH Washington University School of Medicine

Washington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease

Korean-VCI Harmonization Standardization- Neuropsychology Protocol (K-VCIHS-NP)

Extent and Distribution of White Matter Hyperintensities in Normal Aging, Mild Cognitive Impairment and Alzheimer s s Disease

PPMI Cognitive-Behavioral Working Group. Daniel Weintraub, MD

INTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM)

Getting Emerging Planning Professionals Started: What We re All About. Draft for Discussion

European Prevention of Alzheimer s Dementia (EPAD)

2013 AAIC WW-ADNI Meeting, Boston K-ADNI Update

Claims & Underwriting. You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association

Physicians. Remote. Rural

Research on Primary Progressive Aphasia: What It Is Teaching Us About Brain Function and Progression

Proton Pump Inhibitors and Risk of Mild Cognitive Impairment and Dementia

Proton pump inhibitors (PPIs) are a class of drugs prescribed

IEEE Product Safety Engineering Society Board of Directors Meeting. Minutes

Health and Retirement Study Harmonized Cognitive Assessment Protocol (HCAP) Study Protocol Summary

ALZHEIMER'S DISEASE PREVENTION TRIALS

Inclusion of Racial and Ethnic Minorities in Cognitive Research

Structured Pathology Reporting of Cancer Newsletter

21/05/2018. Today s webinar will answer. Presented by: Valorie O Keefe Consultant Psychologist

Yellow Card Centre Scotland Centre for Adverse Reactions to Drugs (Scotland)

National Group for Volunteering in NHS Scotland

Disclosure Statement

The Repeatable Battery for the Assessment of Neuropsychological Status Effort Scale

Scientific Track. Scientific Track At-A-Glance

10 Signs of AD. Sources for Information and Support. Inside this issue: National Centralized Repository. Alzheimer s Disease and Related Dementias

Erin Cullnan Research Assistant, University of Illinois at Chicago

Heritability of Different Forms of Memory in the Late Onset Alzheimer s Disease Family Study

2005 Annual Report of the Center for Alzheimer s Care, Imaging & Research Department of Neurology. Center for Alzheimer s Care, Imaging and Research

The Courageous Leadership Conference

Welcome KATHY SCHWAB, DSA ACTION TEAM CHAIR. Compliance Coordinator, Mayo Clinic Transplant Center

Impact of Alzheimer s Disease, Lewy Body and Vascular Co-Pathologies on Clinical Transition to Dementia in a National Autopsy Cohort

Greater Plains Collaborative Breast Cancer Group. Phase I Wrap up Webinar November 20, 2015

8 th International Research Conference on Adolescents and Adults with FASD. April 18-21, 2018

NIH Public Access Author Manuscript J Alzheimers Dis. Author manuscript; available in PMC 2014 August 14.

Initial Visit Packet Forms

Spring 2011: Central East LHIN Options paper developed

WELCOME Johns Hopkins Institute for Clinical and Translational Research

The Alliance News. Vision. Mission. Wednesday, May 24, 2017 Going Home Rally State Capitol Springfield, Illinois. Issue 69 June 2017.

Introduction. RESEARCHERS DATA DICTIONARY Imaging Data

Chapter President / Past President Call Discussion Notes Monday, February 27, 2017

Fostering open access for Alzheimer s and dementia research: Challenges and the NACC experience

LONGITUDINAL EVALUATION OF COGNITION AFTER STROKE A SCOPING REVIEW

GERIATRIC PRACTICE LEADERSHIP INSTITUTE (GPLI)

Minutes of Healthwatch Sefton Steering Group meeting.

Terms of Reference. Tripartite Planning Committee for First Nations & Aboriginal Maternal & Child Health

Trail making test A 2,3. Memory Logical memory Story A delayed recall 4,5. Rey auditory verbal learning test (RAVLT) 2,6

Eastern Illinois University 2017 Fraternity and Sorority Excellence Awards

Galderma Pre-Board Slide Seminar 2009 July 17-19, 2009

Transcription:

Clinical Task Force Update John C. Morris, MD Friedman Distinguished Professor of Neurology

CTF Report Crosswalk Study Report: Clinical Core Meeting LP Survey: Clinical Core Meeting CTF Progress and Future

Crosswalk Study Report Thanks to Sandy Weintraub and her Work Group: Hiroko Dodge, Steve Ferris, Bruno Giordani, Felicia Goldstein, Joel Kramer, David Loewenstein, Po Lu, Dan Marson, Dan Mungas, David Salmon, Kathie Welsh-Bohmer Thanks to Sarah Monsell, Bud Kukull, and the NACC staff And thanks to the 23 participating ADCs! 797 packets completed (including 159 minority participants) Very good correlations between UDS 2.0 and proposed UDS 3.0 measures: Work Group recommends adoption of UDS 3.0 measures

LP Study Report Thanks to Krista Moulder Thanks to Sarah Monsell, Bud Kukull, and the NACC staff, and to Maria Carrillo and the Alzheimer s Association And thanks to the 18 participating ADCs! Frequency of LP complications Type of needle (Quincke vs. Sprotte) No difference; p<0.28 Amount of post-lp rest Less rest is better (?!) 24% incidence of complication with <1 hr rest vs. 39% with 1 hr (p<0.002)

Origins of the CTF Organized by Tony Phelps and Marcelle Morrison-Bogorad from NIA in 2002 Initial meeting: Oct.12, 2002 (at ADC Directors Meeting, Roosevelt Hotel, New York, NY) 5 Clinical Core Steering Committee members: Charles DeCarli, Norman Foster, Neill Graff-Radford, John Morris, Elaine Peskind 5 NIA appointees: Helena Chui, Jeff Cummings, Steve Ferris, Doug Galasko, Sandra Weintraub Liaisons: Bud Kukull (NACC), Richard Mayeux (Genetics Initiative)

Original CTF Goals To develop expanded and standardized clinical datasets on all ADC subjects to improve clinical assessment and diagnosis, provide data in support of current projects, and to stimulate research Limitations of the Minimum Dataset Primarily cross-sectional data Non-uniform; e.g., no information on diagnostic processes for contributed cases Incomplete (25% missing data) CTF principles Data collected longitudinally Focus on cognitively normal aging and MCI/early stage symptomatic AD; address later FTLD, VaD, and DLB

CTF Leadership Accomplishing goal of NIA- mandated new standardized clinical and cognitive protocol to be used uniformly across all ADCs meant CHANGE, thus RESENTMENT & RESISTANCE Essential qualities for CTF Chair Wise and creative Charismatic and inspirational Confident and positive Debonair and dashing EF Hutton-like The Most Interesting Man in the World

CTF Process I. Review existing ADC clinical and neuropsychological protocols to evaluate current measures and instruments for: Frequency of use Ease of use Reliability Value in characterizing MCI/early stage AD and CN aging Informant report is essential to clinically assess both CN and MCI/early stage AD individuals Allow existing measures and batteries already in use at ADCs to be continued

CTF Process II. Iterative development of the Uniform Dataset with input from all ADCs: surveys, comments, reports at all ADC Directors Meetings. Animated discussions with slings and arrows

CTF: Adoption of UDS Formally approved by the ADCs at the October 2, 2004, Directors Meeting (Westin Harbour Castle Hotel, Toronto, Canada) CTF and NACC then developed forms and codebook, with each version circulated by email to all ADCs for review and comment After finalization of forms, UDS implemented in September 2005 Standardization and Training Meeting for all ADCs and ADNI sites held November 18, 2005, at the Chicago (IL) O Hare Hilton Hotel

The UDS is Now Well Established Over time, growing acceptance and recognition of the value of the dataset 30,327 Initial Visit Packets and 59,553 Follow-Up Assessments (including 3,741 with 6 or more annual assessments) submitted to NACC by 4-21-14 340 investigator requests to NACC for UDS data and growing: 13 requests in 2007, 100 in 2013 373 Cumulative UDS Publications: (Courtesy of Sarah Monsell, NACC)

Improvements in the UDS The UDS is far from perfect and continues to evolve V2 implemented February 2008 FTLD module implemented January 2012 Now, V3 to be implemented Streamline: e.g., drop Form A5 Health History from followup packets Nonproprietary measures» MMSE MoCA» WMS LM I and II Craft story» BNT MINT» WMS Digit Span Number Span» FTLD module: Benson Complex Figure and Letter Fluency (F and L)

UDS V3 Implementation CTF has reviewed draft forms, meets this afternoon After discussion/approval of forms, the UDS V3 will be distributed to all ADCs for review and comment (email) Deadline to submit comments No response to CTF/NACC by deadline constitutes approval of UDS V3 Target implementation: July-August 2014

The Future of the CTF The UDS will continue to evolve More modules (e.g., DLB) Incorporation of biomarkers into diagnostic algorithms After UDS V3 implemented, I will relinquish chairing the CTF; new leadership anticipated for Oct 2014 ADC Directors Meeting As I step down, I bequeath my successor